The Celera paper: sequencing by random shotgun cloning

In the February 16 Science, Venter et al. announce the sequencing of the euchromatic portion of the human genome by a whole-genome shotgun sequencing approach (Science 2001, 291:1304-1350). The sequencing achievement was accomplished by Celera Genomics in nine months in a factory-scale project involving 300 automatic squencing machines (ABI PRISM 3700) producing 175,000 sequence-reads per day. The company generated 14.8 gigabases (Gb) of DNA sequence and combined data with the public GenBank) da

Written byJonathan Weitzman
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In the February 16 Science, Venter et al. announce the sequencing of the euchromatic portion of the human genome by a whole-genome shotgun sequencing approach (Science 2001, 291:1304-1350). The sequencing achievement was accomplished by Celera Genomics in nine months in a factory-scale project involving 300 automatic squencing machines (ABI PRISM 3700) producing 175,000 sequence-reads per day. The company generated 14.8 gigabases (Gb) of DNA sequence and combined data with the public GenBank) database to generate a 2.91 Gb consensus sequence (94% coverage) representing over eight-fold coverage of the genome.

Venter et al. constructed a series of high-quality plasmid libraries (with 2, 10 and 50 kilobase inserts) from five individual DNA donors of diverse ethnic origin. Data from paired sequence reads (averaging 543 basepairs (bp)) were pooled with GenBank data that had been shredded into 550 bp fragments. The authors used two different assembly strategies: whole-genome assembly (WGA) or a compartmentalized ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies